No Data
No Data
Express News | Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
Analysts Conflicted on These Healthcare Names: Daiichi Sankyo Company (OtherDSKYF), Inovio Pharmaceuticals (INO) and Molina Healthcare (MOH)
H.C. Wainwright Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Maintains Target Price $15
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $15 Price Target
Inovio Pharmaceuticals Analyst Ratings
No Data